Study identifier:D4750C00001
ClinicalTrials.gov identifier:NCT02036645
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects with Mild to Moderate Alzheimer’s Disease.
Mild-Moderate Alzheimer's Disease, Healthy Elderly
Phase 1
No
-
All
77
Interventional
55 Years - 85 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Feb 2019 by AstraZeneca
AstraZeneca
-
The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.
Location
Location
Hallandale Beach, FL, United States, 33009
Location
Glendale, CA, United States, 91206
Location
Baltimore, MD, United States, 21225
Location
Orlando, FL, United States, 32806
Location
Long Beach, CA, United States, 90806
Location
Salt Lake City, UT, United States, 84106
Location
Miami, FL, United States, 33165
Location
Hialeah, FL, United States, 33012
Arms | Assigned Interventions |
---|---|
Experimental: MEDI1814 IV Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg. | Biological/Vaccine: MEDI1814 for IV injection Monoclonal antibody for IV Injection |
Placebo Comparator: IV Placebo Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg. | Biological/Vaccine: MEDI1814 for IV injection Monoclonal antibody for IV Injection Biological/Vaccine: IV Placebo Placebo for IV injection |
Experimental: MEDI1814 Sub Cutaneous Injection 2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort | Biological/Vaccine: MEDI1814 for Subcutaneous Injection Monoclonal antibody for subcutaneous injection |
Placebo Comparator: Subcutaneous Placebo 2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort | Biological/Vaccine: Placebo for Subcutaneous Injection Subcutaneous Placebo Injection |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.